108 related articles for article (PubMed ID: 27524220)
1. Effect of Combination of Angiotensin-Converting Enzyme Inhibitors and Vitamin D Receptor Activators on Cardiac Oxidative Stress in Diabetic Rats.
Ali TM; Mehanna OM; Elsaid AG; Askary AE
Am J Med Sci; 2016 Aug; 352(2):208-14. PubMed ID: 27524220
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats.
Husain K; Ferder L; Mizobuchi M; Finch J; Slatopolsky E
Am J Nephrol; 2009; 29(5):465-72. PubMed ID: 19033720
[TBL] [Abstract][Full Text] [Related]
3. Effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats.
Finch JL; Suarez EB; Husain K; Ferder L; Cardema MC; Glenn DJ; Gardner DG; Liapis H; Slatopolsky E
Am J Physiol Renal Physiol; 2012 Jan; 302(1):F141-9. PubMed ID: 21957179
[TBL] [Abstract][Full Text] [Related]
4. Effects of enalapril and paricalcitol treatment on diabetic nephropathy and renal expressions of TNF-α, p53, caspase-3 and Bcl-2 in STZ-induced diabetic rats.
Ahmed OM; Ali TM; Abdel Gaid MA; Elberry AA
PLoS One; 2019; 14(9):e0214349. PubMed ID: 31527864
[TBL] [Abstract][Full Text] [Related]
5. Effect of paricalcitol on pancreatic oxidative stress, inflammatory markers, and glycemic status in diabetic rats.
Ali TM; El Esawy B; Elaskary A
Ir J Med Sci; 2018 Feb; 187(1):75-84. PubMed ID: 28551720
[TBL] [Abstract][Full Text] [Related]
6. Renoprotective effects of combination of angiotensin converting enzyme inhibitor with mycophenolate mofetil in diabetic rats.
Wu YG; Lin H; Qian H; Zhao M; Qi XM; Wu GZ; Lin ST
Inflamm Res; 2006 May; 55(5):192-9. PubMed ID: 16830106
[TBL] [Abstract][Full Text] [Related]
7. Enalapril attenuates oxidative stress in diabetic rats.
de Cavanagh EM; Inserra F; Toblli J; Stella I; Fraga CG; Ferder L
Hypertension; 2001 Nov; 38(5):1130-6. PubMed ID: 11711510
[TBL] [Abstract][Full Text] [Related]
8. Adiponectin expression and the cardioprotective role of the vitamin D receptor activator paricalcitol and the angiotensin converting enzyme inhibitor enalapril in ApoE-deficient mice.
Suarez-Martinez E; Husain K; Ferder L
Ther Adv Cardiovasc Dis; 2014 Dec; 8(6):224-36. PubMed ID: 25037058
[TBL] [Abstract][Full Text] [Related]
9. Combination Therapy with Enalapril and Paricalcitol Ameliorates Streptozotocin Diabetes-Induced Testicular Dysfunction in Rats via Mitigation of Inflammation, Apoptosis, and Oxidative Stress.
Elsaeed MY; Mehanna OM; Abd-Allah EE; Hassan MG; Ahmed WMS; Moustafa AEGA; Eldesoky GE; Hammad AM; Elgazzar UB; Elnady MR; Abd-Allah FM; Shipl WM; Younes AM; Magar MR; Amer AE; Abbas MAM; Elhamaky KSA; Hassan MHM
Pathophysiology; 2023 Nov; 30(4):567-585. PubMed ID: 38133142
[TBL] [Abstract][Full Text] [Related]
10. Effects of paricalcitol and aliskiren combination therapy on experimental diabetic nephropathy model in rats.
Eren Z; Günal MY; Bakir EA; Coban J; Çağlayan B; Ekimci N; Ethemoglu S; Albayrak O; Akdeniz T; Demirel GY; Kiliç E; Kantarci G
Kidney Blood Press Res; 2014; 39(6):581-90. PubMed ID: 25532067
[TBL] [Abstract][Full Text] [Related]
11. Blockade of the renin-angiotensin system improves cerebral microcirculatory perfusion in diabetic hypertensive rats.
Estato V; Obadia N; Carvalho-Tavares J; Freitas FS; Reis P; Castro-Faria Neto H; Lessa MA; Tibiriçá E
Microvasc Res; 2013 May; 87():41-9. PubMed ID: 23466285
[TBL] [Abstract][Full Text] [Related]
12. Low-dose enalapril reduces angiotensin II and attenuates diabetic-induced cardiac and autonomic dysfunctions.
Malfitano C; De Angelis K; Fernandes T; Wichi RB; Rosa K; Pazzine M; Mostarda C; Ronchi FA; Oliveira EM; Casarini DE; Irigoyen MC
J Cardiovasc Pharmacol; 2012 Jan; 59(1):58-65. PubMed ID: 21921804
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats.
Mizobuchi M; Morrissey J; Finch JL; Martin DR; Liapis H; Akizawa T; Slatopolsky E
J Am Soc Nephrol; 2007 Jun; 18(6):1796-806. PubMed ID: 17513326
[TBL] [Abstract][Full Text] [Related]
14. The Therapeutic Effect of Active Vitamin D Supplementation in Preventing the Progression of Diabetic Nephropathy in a Diabetic Mouse Model.
Nakhoul N; Thawko T; Farber E; Dahan I; Tadmor H; Nakhoul R; Hanut A; Salameh G; Shagrawy I; Nakhoul F
J Diabetes Res; 2020; 2020():7907605. PubMed ID: 33294462
[TBL] [Abstract][Full Text] [Related]
15. ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats.
Coppey LJ; Davidson EP; Rinehart TW; Gellett JS; Oltman CL; Lund DD; Yorek MA
Diabetes; 2006 Feb; 55(2):341-8. PubMed ID: 16443766
[TBL] [Abstract][Full Text] [Related]
16. Protective effects of enalapril in streptozotocin-induced diabetic rat: studies of DNA damage, apoptosis and expression of CCN2 in the heart, kidney and liver.
Kushwaha S; Vikram A; Jena GB
J Appl Toxicol; 2012 Sep; 32(9):662-72. PubMed ID: 21416479
[TBL] [Abstract][Full Text] [Related]
17. Cardiac and renal effects of atrasentan in combination with enalapril and paricalcitol in uremic rats.
Ritter C; Zhang S; Finch JL; Liapis H; Suarez E; Ferder L; Delmez J; Slatopolsky E
Kidney Blood Press Res; 2014; 39(4):340-52. PubMed ID: 25300759
[TBL] [Abstract][Full Text] [Related]
18. Impaired Corneal Sensation and Nerve Loss in a Type 2 Rat Model of Chronic Diabetes Is Reversible With Combination Therapy of Menhaden Oil, α-Lipoic Acid, and Enalapril.
Davidson EP; Coppey LJ; Shevalye H; Obrosov A; Kardon RH; Yorek MA
Cornea; 2017 Jun; 36(6):725-731. PubMed ID: 28476051
[TBL] [Abstract][Full Text] [Related]
19. Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas.
Husain K; Suarez E; Isidro A; Ferder L
Am J Nephrol; 2010; 32(4):296-304. PubMed ID: 20720404
[TBL] [Abstract][Full Text] [Related]
20. Effect of combination therapy consisting of enalapril, α-lipoic acid, and menhaden oil on diabetic neuropathy in a high fat/low dose streptozotocin treated rat.
Davidson EP; Holmes A; Coppey LJ; Yorek MA
Eur J Pharmacol; 2015 Oct; 765():258-67. PubMed ID: 26291662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
